|
Jul 26
|
AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation
|
|
Jul 25
|
AstraZeneca (LSE:AZN) Showcases Promising Results For Gefurulimab In Global Myasthenia Gravis Study
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 25
|
Bristol Myers shuffles its executive ranks with new CMO
|
|
Jul 24
|
gMG race hots up as AstraZeneca’s star candidate meets Phase III targets
|
|
Jul 24
|
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
|
|
Jul 24
|
Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche
|
|
Jul 24
|
Insights Into Astrazeneca (AZN) Q2: Wall Street Projections for Key Metrics
|
|
Jul 24
|
LUNGevity Foundation Joins 2025 LungXperience Tour to Promote Lung Health and Early Detection Across the U.S.
|
|
Jul 24
|
AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial
|
|
Jul 23
|
AstraZeneca (LSE:AZN) Commits US$50 Billion For US Expansion By 2030
|
|
Jul 23
|
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
|
|
Jul 23
|
AstraZeneca announces $50bn US investment plans by 2030
|
|
Jul 23
|
Trump Announces Japan Trade Pact, Revises Trade Terms With Indonesia, Philippines
|
|
Jul 22
|
AstraZeneca Announces $50B US Investment Amid Pharma Tariff Threat
|
|
Jul 22
|
China innovation and deals are good for biotech: AstraZeneca CEO
|
|
Jul 22
|
Pharma sector outlook as Trump's drug tariff deadline looms
|
|
Jul 22
|
Corporate Earnings, Trade Developments Leave Equity Markets Mixed Intraday
|
|
Jul 22
|
AstraZeneca to invest $50 bn in the US as tariff threat looms
|
|
Jul 22
|
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
|